Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation

被引：8
|
作者：
Plitt, Anna [1 ]
Ruff, Christian T. [2 ]
Giugliano, Robert P. [2 ]
机构：
[1] Mt Sinai Hosp, Dept Internal Med, One Gustave L Levy Pl, New York, NY 10029 USA
[2] Brigham & Womens Hosp, TIMI Study Grp, Div Cardiovasc, 350 Longwood Ave,1st Floor Off, Boston, MA 02115 USA
来源：
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2016年 / 30卷 / 05期
关键词：
Atrial fibrillation; NOAC; Dabigatran; Rivaroxaban; Apixaban; Edoxaban; FACTOR XA INHIBITOR; DIRECT THROMBIN INHIBITOR; DABIGATRAN ETEXILATE; RENAL-FUNCTION; RISK-FACTORS; WARFARIN; RIVAROXABAN; REVERSAL; CARDIOVERSION; APIXABAN;
D O I：
10.1016/j.hoc.2016.05.002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
For more than 50 years, vitamin K antagonists (VKAs) have been the standard of care for treatment of atrial fibrillation (AF). However, the numerous limitations of VKAs have led to the development of non-VKA oral anticoagulants (NOACs). There are 4 NOACs currently approved for prevention of thromboembolism in patients with nonvalvular AF. This article provides an overview of AF, summarizes basic properties of NOACs, and reviews the landmark trials. Current data on use of NOACs in special populations and specific clinical scenarios are also presented. Lastly, recommendations from experts on controversial topics of bleeding management and reversal are described.
引用
收藏
页码：1019 / +
页数：17
相关论文
共 50 条
  • [1] Non-vitamin K antagonist oral anticoagulants in valvular atrial fibrillation
    Basaran, Ozcan
    Dogan, Volkan
    Sahin, Cem
    Biteker, Murat
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 212 : 357 - 357
  • [2] Non-Vitamin K Antagonist Oral Anticoagulants in the Treatment of Atrial Fibrillation
    Fanaroff, Alexander C.
    Ohman, E. Magnus
    [J]. ANNUAL REVIEW OF MEDICINE, VOL 70, 2019, 70 : 61 - 75
  • [3] How safe are non-vitamin K antagonist oral anticoagulants in atrial fibrillation?
    De Caterina, Raffaele
    [J]. EUROPEAN HEART JOURNAL SUPPLEMENTS, 2016, 18 (0I) : 1 - 6
  • [4] Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Thrombocytopenia
    Janion-Sadowska, Agnieszka
    Papuga-Szela, Elbieta
    Lukaszuk, Robert
    Chrapek, Magdalena
    Undas, Anetta
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2018, 72 (03) : 153 - 160
  • [5] Non-vitamin K antagonist oral anticoagulants in cancer patients with atrial fibrillation
    Undas, Anetta
    Drabik, Leszek
    [J]. ANATOLIAN JOURNAL OF CARDIOLOGY, 2020, 23 (01): : 10 - 18
  • [6] Cessation of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
    Middeldorp, Melissa E.
    Gupta, Aashray
    Elliott, Adrian
    Kadhim, Kadhim
    Thiyagarajah, Anand
    Gallagher, Celine
    Hendriks, Jeroen
    Linz, Dominik
    Emami, Mehrdad
    Mahajan, Rajiv
    Lau, Dennis
    Sanders, Prashanthan
    [J]. HEART, 2021, 107 (12) : 971 - 976
  • [7] The safety and efficacy of non-vitamin K antagonist oral anticoagulants in atrial fibrillation in the elderly
    Patti, Giuseppe
    Cavallari, Ilaria
    Hanon, Olivier
    De Caterina, Raffaele
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 265 : 118 - 124
  • [8] Non-vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation
    Giugliano, Robert P.
    [J]. EUROPEAN HEART JOURNAL SUPPLEMENTS, 2022, 24 : A1 - A10
  • [9] Reply to "Non-vitamin K antagonist oral anticoagulants for atrial fibrillation in obese patients"
    Gupta, Rajeev
    Desai, Rupak
    Gupta, Neelesh
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2020, 130 : 167 - 168
  • [10] Use of non-vitamin K antagonist oral anticoagulants in frail patients with atrial fibrillation
    Ortigoza, Daniel, V
    Valentino, Mariana
    [J]. REVISTA DE LA FEDERACION ARGENTINA DE CARDIOLOGIA, 2021, 50 (02): : 43 - 48
12345